PL3003284T3 - Formulacje farmaceutyczne inhibitora 5 hydroksylazy hif - Google Patents

Formulacje farmaceutyczne inhibitora 5 hydroksylazy hif

Info

Publication number
PL3003284T3
PL3003284T3 PL14735770T PL14735770T PL3003284T3 PL 3003284 T3 PL3003284 T3 PL 3003284T3 PL 14735770 T PL14735770 T PL 14735770T PL 14735770 T PL14735770 T PL 14735770T PL 3003284 T3 PL3003284 T3 PL 3003284T3
Authority
PL
Poland
Prior art keywords
pharmaceutical formulations
hydroxylase inhibitor
hif hydroxylase
hif
inhibitor
Prior art date
Application number
PL14735770T
Other languages
English (en)
Inventor
David CONCA
Lee Allen Flippin
Scott David Leigh
Claudia WITSCHI
Lee Robert Wright
Original Assignee
Fibrogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3003284(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen, Inc. filed Critical Fibrogen, Inc.
Publication of PL3003284T3 publication Critical patent/PL3003284T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14735770T 2013-06-06 2014-06-05 Formulacje farmaceutyczne inhibitora 5 hydroksylazy hif PL3003284T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06
PCT/US2014/041021 WO2014197660A1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor
EP14735770.1A EP3003284B1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Publications (1)

Publication Number Publication Date
PL3003284T3 true PL3003284T3 (pl) 2020-08-10

Family

ID=51063834

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14735770T PL3003284T3 (pl) 2013-06-06 2014-06-05 Formulacje farmaceutyczne inhibitora 5 hydroksylazy hif

Country Status (24)

Country Link
US (3) US20160120859A1 (pl)
EP (2) EP3003284B1 (pl)
JP (4) JP6604941B2 (pl)
KR (3) KR102291860B1 (pl)
CN (5) CN111728952A (pl)
AU (1) AU2014274890B2 (pl)
CA (1) CA2914049C (pl)
CY (1) CY1122951T1 (pl)
DK (1) DK3003284T3 (pl)
ES (1) ES2786924T3 (pl)
HK (1) HK1222550A1 (pl)
HR (1) HRP20200615T1 (pl)
HU (1) HUE049623T2 (pl)
IL (3) IL296484A (pl)
LT (1) LT3003284T (pl)
ME (1) ME03777B (pl)
MX (3) MX2015016536A (pl)
PL (1) PL3003284T3 (pl)
PT (1) PT3003284T (pl)
RS (1) RS60464B1 (pl)
SG (1) SG11201509764RA (pl)
SI (1) SI3003284T1 (pl)
WO (1) WO2014197660A1 (pl)
ZA (1) ZA201508712B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
EP3219706A1 (en) 2012-07-16 2017-09-20 Fibrogen, Inc. Process for making isoquinoline compounds
PL3470397T3 (pl) 2012-07-16 2022-06-20 Fibrogen, Inc. Postacie krystaliczne inhibitora hydroksylazy prolilowej
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
ES2786924T3 (es) 2013-06-06 2020-10-14 Fibrogen Inc Formulaciones farmacéuticas que comprenden un inhibidor de hidroxilasa del HIF
PT3277270T (pt) * 2015-04-01 2021-12-07 Akebia Therapeutics Inc Composições e métodos de tratamento de anemia
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
CN111065625A (zh) 2017-09-04 2020-04-24 桑多斯股份公司 口服可利用的hif脯氨酰羟化酶抑制剂的共晶
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
JP2023518392A (ja) * 2020-03-17 2023-05-01 ザイダス ライフサイエンシズ リミティド Ｈｉｆプロリルヒドロキシラーゼ阻害剤を含む製剤組成物
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CN114796280A (zh) * 2022-06-15 2022-07-29 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
CN102552261A (zh) 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
BR0317349A (pt) 2002-12-16 2005-11-16 Kissei Pharmaceutical Droga sólida para uso oral
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US20070042937A1 (en) 2003-08-01 2007-02-22 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
EP1726306B1 (en) 2004-03-16 2013-10-30 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
AU2006254897A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
ATE470439T1 (de) 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
AU2006309826B2 (en) 2005-10-31 2012-01-19 Kowa Co., Ltd. Pharmaceutical preparation having excellent photostability
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
EP2476669A1 (en) 2006-01-27 2012-07-18 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
AU2006337648A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
KR20080097446A (ko) 2006-02-16 2008-11-05 피브로겐, 인크. 뇌졸중의 치료를 위한 화합물과 방법
JP5111491B2 (ja) 2006-04-04 2013-01-09 フィブロジェン， インコーポレイテッド ピロロ−およびピラゾロ−ピリミジン化合物、およびそれらの使用方法
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
JP5683058B2 (ja) 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
AU2008309385B2 (en) * 2007-10-12 2011-10-20 Astrazeneca Ab Zibotentan composition containing mannitol and/or microcrystalline cellulose
CN101917996A (zh) 2007-11-02 2010-12-15 法布罗根股份有限公司 降低血压的方法
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US20110039885A1 (en) 2007-12-06 2011-02-17 Fibrogen, Inc. Methods for increasing endothelial progenitor cells
EP2231156A1 (en) 2007-12-07 2010-09-29 Fibrogen, Inc. Methods for increasing white blood cells
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
US20110263642A1 (en) 2008-08-26 2011-10-27 Fibrogen, Inc. Methods for treatment of multiple sclerosis
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
WO2010087462A1 (ja) 2009-01-29 2010-08-05 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
US20140171465A1 (en) * 2011-01-13 2014-06-19 Fibrogen, Inc. Methods For Increasing Reticulocyte Hemoglobin Content
CN103429240A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加平均红细胞体积的方法
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
WO2013070908A1 (en) 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
CN104470899B (zh) 2012-03-09 2017-12-26 菲布罗根有限公司 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物
PL3470397T3 (pl) 2012-07-16 2022-06-20 Fibrogen, Inc. Postacie krystaliczne inhibitora hydroksylazy prolilowej
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP3219706A1 (en) 2012-07-16 2017-09-20 Fibrogen, Inc. Process for making isoquinoline compounds
ES2694297T3 (es) 2013-01-24 2018-12-19 Fibrogen, Inc. Formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidroxi-isoquinolina-3-carbonilo]-amino}-acético
ES2786924T3 (es) 2013-06-06 2020-10-14 Fibrogen Inc Formulaciones farmacéuticas que comprenden un inhibidor de hidroxilasa del HIF

Also Published As

Publication number Publication date
EP3003284B1 (en) 2020-02-12
WO2014197660A1 (en) 2014-12-11
US10765672B2 (en) 2020-09-08
CA2914049C (en) 2021-10-12
RU2015151056A (ru) 2017-07-14
JP2019137703A (ja) 2019-08-22
US20220054474A1 (en) 2022-02-24
CN111728950A (zh) 2020-10-02
JP6604941B2 (ja) 2019-11-13
AU2014274890A1 (en) 2015-12-17
CN111728951A (zh) 2020-10-02
RU2681304C2 (ru) 2019-03-06
RU2015151056A3 (pl) 2018-05-03
IL242759A (pl) 2015-12-31
JP2016523846A (ja) 2016-08-12
DK3003284T3 (da) 2020-03-30
JP2021100971A (ja) 2021-07-08
SG11201509764RA (en) 2015-12-30
AU2014274890B2 (en) 2019-10-03
KR20220164069A (ko) 2022-12-12
IL298998B1 (en) 2024-03-01
ES2786924T3 (es) 2020-10-14
KR20160018514A (ko) 2016-02-17
MX2020003096A (es) 2020-08-17
CN111728952A (zh) 2020-10-02
IL242759B1 (en) 2023-01-01
BR112015029693A2 (pt) 2017-07-25
LT3003284T (lt) 2020-04-27
MX2015016536A (es) 2016-08-11
BR112015029693A8 (pt) 2019-12-24
CN110448537A (zh) 2019-11-15
HRP20200615T1 (hr) 2020-07-10
ME03777B (me) 2021-04-20
EP3708154A1 (en) 2020-09-16
CY1122951T1 (el) 2021-10-29
US20190008846A1 (en) 2019-01-10
NZ714554A (en) 2021-06-25
CA2914049A1 (en) 2014-12-11
SI3003284T1 (sl) 2020-08-31
NZ754196A (en) 2021-06-25
CN105377242A (zh) 2016-03-02
HUE049623T2 (hu) 2020-09-28
RS60464B1 (sr) 2020-07-31
JP6861758B2 (ja) 2021-04-21
US20160120859A1 (en) 2016-05-05
EP3003284A1 (en) 2016-04-13
MX2022011225A (es) 2022-10-07
ZA201508712B (en) 2020-07-29
IL298998A (en) 2023-02-01
KR102291860B1 (ko) 2021-08-20
PT3003284T (pt) 2020-08-10
IL242759B2 (en) 2023-05-01
IL296484A (en) 2022-11-01
KR20210104173A (ko) 2021-08-24
JP2023068197A (ja) 2023-05-16
HK1222550A1 (zh) 2017-07-07

Similar Documents

Publication Publication Date Title
HK1222550A1 (zh) 羥化酶抑制劑的藥物製劑
IL285528A (en) A process for preparing a pde4 inhibitor
PL3080100T3 (pl) Inhibitory lizyno-specyficznej demetylazy-1
HK1248217A1 (zh) 選擇性cdk4/6抑制劑的固態形式
HK1206743A1 (en) 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors hif 4--
IL264259A (en) Oral formulations of pyrrolidine derivatives
HK1220125A1 (zh) 拉喹莫德的透皮配方
HK1204916A1 (en) Pharmaceutical application of anhydroicaritin
AP2014007760A0 (en) Stabilized pharmaceutical formulations of a potentHCV inhibitor
PL2801352T3 (pl) Ulegające rozpadowi w jamie ustnej formulacje lakozamidu
GB201320835D0 (en) HIF inhibitors
EP3052475A4 (en) Pharmaceutical use of 3-benzylsulfonylpropionitrile